|
1.3 PRIX NOBEL
|
|
|
|
1.4 BIOLOGIE - TECHNOS, MODÈLES
|
|
|
|
2. ETIOLOGIE
|
|
|
Familial risk of colorectal cancer: the genes only tell part of the story [DKFZ]
|
|
|
|
|
|
On the basis of a current epidemiological study, scientists at the German Cancer Research Center (DKFZ) conclude that the role of genes has been overestimated in patients with a higher familial risk of colorectal cancer. Other risk factors such as family dietary habits presumably have a greater impact that previously assumed. This will have implications for future calculations of individual risk and for the ensuing recommendations.
|
|
|
|
|
|
|
Heartburn Drugs and Cancer: What Are the Risks? [WebMD]
|
|
|
|
|
|
Valisure is working with researchers at Memorial Sloan Kettering Cancer Center to dig deeper into the risks. They hope to be able to pinpoint which types of cancer are linked to NDMA soon, so people who’ve been taking ranitidine for years will know what to monitor with their doctors.
|
|
|
|
|
|
|
3.1.1 PRÉVENTION - TABAC - E-CIGS
|
|
|
|
|
|
4. DÉPISTAGE, DIAGNOSTIC ET PRONOSTIC
|
|
|
|
4.15 DÉP., DIAG. & PRONO. - IMAGERIE
|
|
|
|
5.10 TRAITEMENTS - ESSAIS
|
|
|
Adaptive Trials [In The Pipeline]
|
|
|
|
|
|
The paper under discussion is particularly geared toward adaptive platform trials, which is the sort of thing you might run if you’re comparing several oncology clinical candidates or combinations (for example).
|
|
|
|
|
|
|
|
5.12 IMMUNOTHÉRAPIES
|
|
|
|
|
5.12.11 IMMUNOTHÉRAPIES - PRÉ-CLINIQUE
|
|
|
|
5.3 TRAITEMENTS - FDA, EMA, NICE...
|
|
|
|
|
5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)
|
|
|
|
|
|
5.6 ESMO
|
|
|
|
5.6.14 ESMO - OVAIRE
|
|
|
GSK, AstraZeneca rivalry takes center stage at cancer conference [Reuters]
|
|
|
|
|
|
Both companies have already flagged that their respective drug candidates, part of a class known as PARP inhibitors, did well in staving off a return of ovarian cancer in women that had responded to initial standard treatment.GSK and Astra, which are also competing in respiratory drugs, have held back full trial details for the ESMO event.
|
|
|
|
|
|
|
6.1 OBSERVATION
|
|
|
|
6.10 POLITIQUES
|
|
|
|
6.11 PATIENTS
|
|
|
|
|
6.6 PUBLICATIONS
|
|
|
|
6.7 DMP, BIG DATA & APPLIS
|
|
|
|
|
6.9 CONTROVERSES
|
|
|
Seven years later, NIH center that aims to speed drugs to market faces challenges [Science]
|
|
|
|
|
|
Some accused NIH of wanting to become a drug company or solve the pharmaceutical industry's challenges—a notion one former CEO likened to believing in fairies. It fell to Austin to prove that the National Center for Advancing Translational Sciences (NCATS) wasn't going to compete with industry, but could give it powerful new tools. After 7 years, the jury is still out.
|
|
|
|
|
|